Sign Out
Epirubicin has produced responses in a wide range of neoplastic conditions, including breast, ovarian, gastric, lung, liver and colorectal carcinomas, malignant lymphomas, leukemias, multiple myeloma and soft tissue sarcoma.
Intravesical administration of epirubicin has been found to be beneficial in the treatment of superficial bladder cancer (carcinoma-in-situ) and in the prophylaxis of recurrences after transurethral resection.
Continue with Google